Literature DB >> 1922083

Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression.

V W Merz1, G J Miller, T Krebs, T L Timme, D Kadmon, S H Park, S Egawa, P T Scardino, T C Thompson.   

Abstract

Mouse prostate reconstitution is a useful model for studying the progression of ras + myc-induced carcinomas. When these oncogenes were introduced into both the epithelial and the mesenchymal compartments, poorly differentiated adenocarcinomas resulted. Restricted introduction of both oncogenes into the epithelium produced epithelial hyperplasia. Malignancies were produced in two out of 17 cases of selectively transformed epithelium, suggesting that the hyperplastic condition represents a premalignant phenotype. Restricted introduction of both oncogenes into the mesenchyme produced only mesenchymal dysplasia. Transforming growth factor-beta 1 (TGF-beta 1) and beta 3 (TGF-beta 3) mRNA levels were elevated in the ras + myc-induced carcinomas when compared to the normal controls or to the epithelial hyperplasias. In contrast, TGF-beta 2 mRNA levels were similar in all control and ras + myc-induced carcinomas. Elevated TGF-beta 1 mRNA levels were also found in mesenchymal dysplasia pointing to a potential paracrine activity by the ras + myc transformed mesenchyme. We conclude that elevated TGF-beta 1 and beta 3 are correlated with progression to malignancy and that mesenchyme derived TGF-beta 1 may play an important role in the promotion of ras + myc-induced carcinomas in this model system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1922083     DOI: 10.1210/mend-5-4-503

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  10 in total

Review 1.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

2.  Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines.

Authors:  S J Hall; T C Thompson
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

3.  Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma.

Authors:  G Sehgal; J Hua; E J Bernhard; I Sehgal; T C Thompson; R J Muschel
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

4.  Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities.

Authors:  T L Timme; G Yang; L D Truong; D Kadmon; S H Park; T C Thompson
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 5.  Transforming growth factor-beta and prostate cancer.

Authors:  M S Steiner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

6.  Paracrine communication between malignant and non-malignant prostate epithelial cells in culture alters growth rate, matrix protease secretion and in vitro invasion.

Authors:  Andrea H Greiff; William M Fischer; Inder Sehgal
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 7.  Rodent models for targeted oncogenesis of the prostate gland.

Authors:  R Buttyan; K Slawin
Journal:  Cancer Metastasis Rev       Date:  1993-03       Impact factor: 9.264

8.  Enhanced translational efficiency of a novel transforming growth factor beta 3 mRNA in human breast cancer cells.

Authors:  B A Arrick; R L Grendell; L A Griffin
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

9.  Differential expression of transforming growth factor-beta 1 and beta 3 as well as c-fos mRNA in normal human prostate, benign prostatic hyperplasia and prostatic cancer.

Authors:  V W Merz; A M Arnold; U E Studer
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

10.  Induction of transforming growth factor beta in hormonally treated human prostate cancer.

Authors:  G H Muir; A Butta; R J Shearer; C Fisher; D P Dearnaley; K C Flanders; M B Sporn; A A Colletta
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.